Reporter's notebook: AHA/ASA International Stroke Conference
This article was originally published in Scrip
Amid data regarding basic research, stroke prevention, access to adequate care and surgical procedures, some clinical trial results and at least one debate shed light on pharmaceutical interventions at the International Stroke Conference (ISC) hosted by the American Heart Association (AHA) and American Stoke Association (ASA) from 12-14 February in San Diego.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.